Market Signal Briefing

Thu, 20/11/2025 - 15:23

The Coinbase Bitcoin Premium Index measures the price difference between Bitcoin traded on top US exchange Coinbase and the global market average.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Bitcoin has been in the red for four straight weeks. Bitcoin extended its drop from late October, reaching a low of $88,483 this week, to print four red weekly candles. The drop has caused a loss of crucial weekly support, the weekly MA 50 at $102,749.

As a result, the Coinbase Premium Gap dropped as low as -$90, according to CryptoQuant, a sign of strong selling pressure in the U.S.

According to CryptoQuant, selling continues to dominate in the American session. Cumulative trading returns during U.S. hours are negative for the entire month, while Europe and APAC remain flat or slightly positive.

HOT Stories

Bitcoin has been red for four straight weeks.

The Coinbase Premium Gap dropped as low as -$90, which is a sign of strong U.S. selling pressure.

Here’s the key data behind the U.S. investor sell-off 👇 pic.twitter.com/V9liGZmmcs

— CryptoQuant.com (@cryptoquant_com) November 19, 2025 This has resulted in ETF flows turning net negative for three consecutive weeks as outflows continue to weigh on the BTC spot market. Investors pulled more than half a billion dollars from BlackRock's iShares Bitcoin Trust, the largest single-day outflow since the fund’s debut. BlackRock saw $523 million in outflows from the exchange-traded fund on Tuesday, marking the fifth straight day of net outflows and its highest on record.

Bitcoin ETFs are now down $3.98 billion from their all-time high, which is the second-largest drawdown since launch, as the BTC ETF realized price sits at $86,586.

What it meansThe Coinbase Bitcoin Premium Index measures the price difference between Bitcoin traded on top U.S. exchange Coinbase and the global market average. It marks a key indicator of capital flows, institutional activity and market sentiment.

A negative premium suggests Bitcoin is trading for less on Coinbase. This might indicate selling pressure on the market and waning risk appetite among investors.

Related articles

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The market remains bearish as most of the coins are in the red zone, according to CoinMarketCap.

Top coins by CoinMarketCapZEC/USDThe rate of ZEC has rocketed by almost 10% over the last 24 hours.

Image by TradingViewOn the hourly chart, the price of ZEC has made a false breakout of the local resistance of $706. 

You Might Also Like

However, if the daily bar closes near that mark, the upward move may continue to the $720-$730 range.

Image by TradingViewOn the bigger time frame, the situation is rather more bullish than bearish. If a breakout of the $750 level occurs, the accumulated energy might be enough for a price blast to the $800 zone.

Image by TradingViewFrom the midterm point of view, one should focus on the weekly candle's closure in terms of the nearest resistance. If bulls can hold the initiative, there is a chance to see a test of a new all-time high by the end of the month.

ZEC is trading at $703.53 at press time.

Solana ETFs Post Second-Biggest November Inflows as Demand Grows During DownturnSpot SOL exchange-traded funds extended an inflow streak since they began trading on Oct. 28 while bitcoin and ether ETFs bled hundreds of millions of dollars.
Nov 20, 2025, 3:32 p.m.

U.S. spot solana SOL$143.49 exchange-traded funds (ETFs) extended their inflow streak to a 17th straight day on Wednesday, with no net withdrawals since they first started trading Oct. 28.

The funds added $48.5 million on Wednesday, taking cumulative net inflows since inception to $476 million, according to Farside data. Wednesday's inflow was the second-largest this month.

STORY CONTINUES BELOW

The stream of inflows, the longest uninterrupted run of positive flows among the crypto ETFs this year, comes as the more established bitcoin BTC$92,123.27 and ether ETH$3,033.72 products are shedding support.

In November alone, bitcoin ETFs have experienced net outflows of approximately $2.96 billion, while ether ETFs recorded about $107 million, Farside data shows.

Bitwise’s BSOL led Wednesday's inflows with $35.9 million in fresh money, followed by Grayscale’s GSOL at $12.6 million. Fidelity (FSOL) and VanEck (VSOL) added smaller amounts.

The flows into solana ETFs indicate a drive for more exposure to the token even as the crypto market weakens. The CoinDesk 20 Index (CD20) has dropped 12% in the past seven days.

More For You

Protocol Research: GoPlus Security

Nov 14, 2025

What to know:

As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.View Full Report

More For You

Securitize Leverages Plume to Expand Global Real-World Asset Reach

38 minutes ago

Securitize partners with Plume to launch institutional-grade assets on Plume's Nest staking protocol, expanding its DeFi footprint.

What to know:

Securitize partners with Plume to launch institutional-grade assets on Plume's Nest staking protocol, expanding its DeFi footprint.The collaboration connects Securitize's tokenized funds to Plume's network of over 280,000 real-world asset holders.As part of the collab, Bitcoin finance platform Solv plans to pour millions into Plume's RWA vaults.Read full story

TL;DR

SafePal launched a native integration with Hyperliquid, allowing users to trade perpetual futures with up to 40x leverage directly from their wallets.
The V4.10.4 update provides access to the fully on-chain orderbook, support for HyperEVM assets, and a Dapp explorer.
The integration turns SafePal into a native perp trading hub, enabling seamless asset management, transfers, swaps, and trading of BTC and ETH without fees.

SafePal launched a native integration with Hyperliquid, a high-performance DEX specialized in perpetual futures, enabling users to trade with up to 40x leverage directly from their wallets.

The V4.10.4 update provides access to the fully on-chain orderbook, support for HyperEVM assets, and a Dapp explorer to interact with the Hyperliquid ecosystem without leaving the SafePal environment.

With this integration, SafePal aims to build a native perpetual futures trading hub within the wallet, facilitating asset management, token sending and receiving, and seamless and secure perp trading. Available pairs include BTC and ETH, and all operations take place inside the wallet, with no additional fees and no need to use external interfaces.

Hyperliquid combines the speed and user experience of a centralized exchange with the transparency and self-custody of a DEX. Its on-chain orderbook, deep liquidity, and advanced trading tools allow efficient trading without sacrificing control over assets. The integration offers users a complete workflow, from custody to order execution, all within a single environment.

SafePal Becomes a Native Perp Trading Hub
The update also enables managing HyperEVM assets, which can be stored, sent, and received directly from the SafePal app or hardware wallets. Additionally, users can explore Dapps in the Hyperliquid ecosystem through the integrated Dapp Explorer.

The company expects this integration to pave the way for deeper partnerships, such as Walletdrop campaigns, although no specific incentives, new token listings, or additional custody risk mitigations have been announced beyond the standard non-custodial functionality.

Founded in 2018, SafePal is a non-custodial wallet suite backed by Animoca Brands, Binance, and Superscrypt, supporting over 100 blockchains and more than 25 million users across 200 countries and regions. The platform includes tools for swapping, trading, yield, a banking gateway, and a Mastercard. Its SFP token provides discounts, staking boosts, airdrop rewards, and direct conversion to gas tokens

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

FRESNO, Calif.--(BUSINESS WIRE)-- #ERI--ERI, the nation's leading material resource recovery, ITAD, mobility and data destruction/processing provider and largest recycler of electronics, today announced the signing of a commercial processing agreement with American Resources Corporation (NASDAQ:AREC) through American Resources' minority holding in ReElement Technologies Corporation, a leading U.S. innovator in rare earth element (REE) and critical mineral refining. Under the agreement, ERI will levera.

Glen Rock, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (RespireRx or the Company), and its subsidiaries, EndeavourRx LLC (EndeavourRx) and ResolutionRx Ltd (ResolutionRx), collectively, the RespireRx Group, leaders in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, today provides a progress and status report to its stockholders, stakeholders, strategic partners as well as other interested parties.

Dear Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties:

As we prepare to end 2025, we would like to provide you with this open letter summarizing our challenges, the strategies we have implemented and continue to implement to meet those challenges, our accomplishments during 2025 and our 2026 goals and plans. Of course, we can provide no assurance that we will achieve these goals (see cautionary note about forward-looking statements near the end of this letter), but we believe that they are based on realistic assumptions and are reasonably achievable. We will certainly work hard on your behalf to try to achieve what we lay out here.

We have experienced a number of financial challenges, which will come as no surprise to our followers, we have had important successes, particularly with our science and preclinical and clinical development. We have published in peer-reviewed journals several times in 2025, but importantly, these papers and those of prior years have been cited frequently by other peer-reviewed authors, which is an indication of their quality and relevance.

Strategic Restructuring and Grants

ResolutionRx Ltd - In 2023, we created ResolutionRx, currently a wholly-owned, unlisted public company in Australia, as the first in a series of steps that include, but are not limited to financings, research and clinical development, manufacturing, regulatory and compliance, all for the purpose of developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol, an endocannabinoid CB1 and CB2 receptor agonist, for the treatment of obstructive sleep apnea (“OSA”). The Company has contributed certain dronabinol assets and certain liabilities to ResolutionRx.

One of the main purposes for the creation of ResolutionRx was to allow it to participate in the Australian research and development tax incentive (credit) which in the case of ResolutionRx, is a refund of 43.5% of qualified research and development expenditures as reported on ResolutionRx’s Australian tax return. ResolutionRx has arranged with an Australia based fund to establish a finance facility secured by the tax credits in order to finance a substantial percentage of the credit associated with the qualified expenditures over the course of the research and development timeline in advance of the final receipt of the tax credit funds. In addition, ResolutionRx is in late-stage negotiations with a single investor for an equity or equity-linked financing of up to 15% of the research and development budget associated with Australian vendors approved by such investor. There can be no assurance that such investment(s) will consummate. Inherent in this financing is a commitment to list ResolutionRx on the Australian Stock Exchange (ASX). ResolutionRx’s intent is to list on the ASX and one or more public exchanges outside of Australia, including the United States.

EndeavourRx LLC - On January 27, 2025, we formed EndeavourRx, a wholly owned private company as a vehicle for developing AMPAkines and GABAkines, positive allosteric neuromodulators (PAMs) designed to enhance the actions of the neurotransmitters, glutamate and GABA, acting upon the AMPA glutamate and GABA-A receptors, respectively.

AMPAkines

        Traumatic spinal cord injury (SCI) often results in neurogenic bladder dysfunction that produces a plethora of urological complications leading to reductions in the quality of life and an increased risk of premature death. Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020). Current treatment approaches usually require interventions such as catheterization for urinary voiding, which have their own set of risks and potentially significant set of complications. World-wide incidence rates range from 12 to 59 cases per million depending on the country (Amidei et al., Spinal Cord 60:812-819; 2022) and of these 70 - 84% showed neurogenic bladder dysfunction (Kumar et al., World Neurosurgery 113:e345–e363;2018).

Because of the promising animal research at Dr. Fuller’s laboratory (Univ. Florida), our collaborator, the Shirley Ryan AbilityLab (SRAL), one of the pre-eminent SCI treatment centers in the U.S., received notice of a $1.8 million award from the U.S. Department of Defense for Phase 2A and 2B human clinical trials with our AMPAkine CX1739 in spinal cord injured patients. As the Principal Investigator, the clinical trials will be conducted by Dr. Sandhu at the Shirley Ryan AbilityLab in order to determine the safety and efficacy of CX1739, our lead clinical AMPAkine, to improve bladder function in patients after spinal cord injury (SCI).

RespireRx’s responsibility is to manufacture and formulate the clinical material, reinstate the CX1739 IND and collaborate with SRAL. We are in the process of finalizing with SRAL the terms and conditions for a supply agreement.

The U.S. Army Medical Research Acquisition Activity, in support of the Congressionally Directed Medical Research Program (CDMRP), is the awarding and administering acquisition office and this work will be supported by the Department of Defense, in the amount of $1,793,411, through the Spinal Cord Injury Research Program under Award No. HT94252410497. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the Department of Defense.

In addition to studying AMPAkines in the treatment of SCI, we have submitted a grant application to the U.S. National Institutes of Health in order to conduct a Phase 2B clinical trial of CX1739 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a chronic and complex neurodevelopmental condition characterized by an ongoing pattern of inattention and/or hyperactivity-impulsivity that significantly interferes with functioning or development. Symptoms of ADHD often begin between the ages of 3 and 6 and persist during adolescence and adulthood. It is commonly associated with comorbidities such as learning disabilities, anxiety, depression, and substance use disorder, resulting in a substantial financial burden on both families and society. Current pharmacological treatments, including stimulants and non-stimulants have notable limitations. Stimulants only alleviate outward symptoms and offer limited benefit for higher order cognitive processes called executive functions, essential for goal-directed behavior and novel problem-solving. They also carry a risk of misuse and may contribute to substance use disorders. While non-stimulants offer an alternative, their efficacy and tolerability often vary significantly among different patient subgroups. Furthermore, these medications are frequently associated with adverse side effects, including cardiovascular issues that often lead to discontinuation. Thus, there is a pressing need for safer, more effective ADHD treatments that address both core symptoms and underlying cognitive deficits.

CX717 has not only shown unique and desirable properties when given in animal models of ADHD, but has demonstrated safety in human Phase 1 studies, successful receptor target engagement in humans during Phase 2A and efficacy in a successful Phase 2 clinical trial in adult subjects with ADHD. The planned Phase 2B ADHD clinical trial has been designed as a double blind, placebo-controlled study in order to confirm the results in the Phase 2A study, but also to establish the efficacy of CX717 in a larger study.

GABAkines

On September 23, 2025, RespireRx received a Notice of Award from the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), award number 1R44NS143576, under the Small Business Innovation Research (SBIR) program which was created by the U.S. Congress to strengthen the role of small innovative companies in federally supported research and development. The amount of the award is $1,499,869 for the budget period September 23, 2025 through August 31, 2026. The project start date is September 23, 2025 and end date is August 31, 2027, a two-year period. The total amount requested in the application was $2,999,738 over the two-year period. The purpose of the project is to complete the required preclinical toxicology and other related efforts to support the filing of an investigational new drug application (IND) to study in clinical trials, our lead GABAkine, KRM-II-81 for the treatment of epilepsy. This content is solely the responsibility of the Company, and any writings, publications, presentation or similar disclosures are solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Under an Amended and Restated Patent License Agreement entered into as of October 27, 2025 with the University of Wisconsin-Milwaukee (UWM) Research Foundation, Inc. and on behalf of its EndeavourRx LLC subsidiary, RespireRx has in-licensed rights to certain selectively acting GABAkines developed in the laboratory of Dr. James Cook, UWM Distinguished Professor Emeritus, because of their ability to selectively amplify inhibitory neurotransmission at a highly specific, subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx LLC will continue RespireRx’s focus on developing KRM-II-81 for the treatment of epilepsy and pain.

KRM-II-81 has displayed a high degree of anti-seizure activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant animal and other models (34 models). Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy because of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM- II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment-resistant epileptic patients who underwent surgery (3 studies). We have also licensed and characterized the anti-seizure properties of a host of structural analogs of KRM-II-81 that will facilitate the overall development of this program.

In addition, KRM-II-81 has displayed remarkable analgesic activity in a broad range of preclinical studies (7 studies and other GABAkines in our portfolio in 3 additional studies). KRM-II-81 is currently being profiled for its analgesic and side-effect profile by the Division of Translational Research, at the NINDS. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid analgesics that are at the heart of the opioid epidemic.

The UWM Research Foundation (UWMRF) and RespireRx Pharmaceuticals have amended and restated their patent license agreement to better align with current commercialization strategies. Key updates include updates on regulatory milestone-based payments, revising royalty structures, and adjustment of amounts and timing of patent cost reimbursements. The agreement also eliminates prior UWMRF equity provisions in favor of a fixed exit fee tied to certain liquidity events, while clarifying intellectual property definitions and streamlining diligence and reporting obligations. These changes reflect a shared commitment to flexibility and long-term success in advancing innovative neuromodulator programs.

Capital Raising

As we have stated previously, raising capital has been a problem and so we are very pleased that on Nov. 18, 2025, we announced the commencement of a Regulation D, Rule 506(c) exempt offering of securities, across the three entities of the RespireRx Group, RespireRx, EndeavourRx and ResolutionRx. The targeted raise is up to $45 million, and the exclusive Placement Agent is Castle Placement, LLC.

Summary of the Offering

The financing will support the RespireRx Group’s ongoing and future research and development and clinical programs across the three affiliated entities.

Capital Allocation and Use of Proceeds

ResolutionRx (Australia) — $15 million Advancing a proprietary dronabinol formulation for obstructive sleep apnea (OSA), addressing a large global patient population underserved by existing treatments. Proceeds will fund PK/PD studies, a Phase 3 clinical trial, and working capital needs. EndeavourRx LLC (Delaware) — $25 million Developing two innovative drug platforms:
• AMPAkines (CX1739 and CX717) for spinal cord injury and ADHD, supported by a U.S. Department of Defense grant and pending NIH funding.
• GABAkines (KRM-II-81) for treatment-resistant epilepsy and non-opioid pain. Funds will accelerate preclinical, IND-enabling, and clinical development activities.Subject of NIH/NINDS SBIR Notice of Award to RespireRx of $1.5 million for the first year of a two-year grant application totaling $3 million (see above). RespireRx Pharmaceuticals Inc. (Delaware parent) — $5 million Proceeds will support corporate operations, governance, and intellectual property management across the RespireRx Group. SEC Matters

On November 13, 2025, effective November 14, 2025 the Securities and Exchange Commission (“Commission”), in Administrative Proceeding File No. 3-22541, in Release No. 104178 issued an Order Making Findings and Revoking Registration of Securities Pursuant to Section 12(j) of the Securities Exchange Act of 1934.

The Commission stated “The Securities and Exchange Commission (“Commission”) deems it necessary and appropriate for the protection of investors to accept the Offer of Settlement submitted by RespireRx Pharmaceuticals Inc. (CIK No. 849636) (Ticker: RSPI) (“RSPI” or “Respondent”) pursuant to Rule 240(a) of the Rules of Fair Practice of the Commission, 17 C.F.R. §201.240(a), for the purpose of settlement of these proceedings initiated against Respondent on September 11, 2025, pursuant to Section 12(j) of the Securities Exchange Act of 1934 (“Exchange Act”).

The findings were that unsolicited quotations of the common stock of RSPI had been “submitted on the Expert Market of the OTC Link ATS…” and that RSPI had “failed to comply with Exchange Act 13(a) and Rules 13a-1 and 13a-13 thereunder because it had not filed any periodic reports with the Commission since it filed a Form 10-Q for the period ended September 30, 2023.”

Given the findings, the Commission “ORDERED, pursuant to Section 12(j) of the Exchange Act, that registration of each class of the securities of RespireRx Pharmaceuticals Inc…registered pursuant to Section 12 of the Exchange Act be, and hereby, is revoked.” The effective date of the revocation was November 14, 2025.

RSPI made the offer of settlement on September 30, 2025. Between September 30, 2025 and the date of the release, RSPI was awaiting determination as to whether its Offer would be accepted.

The government shut down was effective October 1, 2025 and reopened on November 12, 2025 and the Commission released the acceptance of the settlement on November 13, 2025.

There is no monetary fine.

The registration of our common stock which was the only class of securities previously registered has been revoked.

At this time, the Company plans to register it common stock, and possibly other classes of its stock on Form 10 in the future. Our understanding of the process is that the submission of Form 10 will require the filing of two years of audited financial statements. We currently believe that it would be most efficient from a time, resource and financial perspective to wait until after December 31, 2025 and file Form 10 with December 31, 2024 and December 31, 2025 audited financial statements. We further understand that a filed Form 10 filed under Section 12(g) becomes automatically effective sixty (60) days after filing. We also believe that from the effective date forward we would need to remain current with the required periodic filings and that we will not have to file any of the previously required but unfiled periodic filings. To learn more about Form 10, you may find it informative to read the material in the following link to the Commission website: https://www.sec.gov/files/form10.pdf and other available sources. The foregoing constitute forward-looking statements. You are cautioned to read the Cautionary Note Regarding Forward-Looking Statements below. We can provide no assurance that all or any of these will occur.

Looking Forward

In addition to the above, we intend to complete the discussions and execute a definitive agreement with SRAL.

We have identified two prospective local Australian professionals to serve as directors of ResolutionRx and we are finalizing the documents and agreements to officially bring them on board and replace our current local directors.

We intend to maintain, expand and enhance our intellectual property portfolio.

Pending the receipt of adequate finance, of which no assurance can be provided, we plan to activate or replace our IND for CX717, and engage in research, preclinical and clinical development beyond the scope of existing grant awards and grants applied.

And a Thank You

We would like to thank all of our shareholders, strategic vendors/collaborators, service providers, strategic partners and all other stakeholders for their patience and for standing with us as we advance the RespireRx Group and what we consider to be its very valuable and important assets.

And as we said in a press release/letter on February 10, 2025, we continue to believe that together, we can advance life-changing therapies, create value for our investors and other stakeholders, and positively impact the lives of patients worldwide.

About RespireRx Group

RespireRx Pharmaceuticals Inc. and its subsidiaries, EndeavourRx LLC and ResolutionRx Ltd, collectively, the RespireRx Group is discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (ADHD), recovery from spinal cord injury (SCI), certain neurological orphan diseases and obstructive sleep apnea (OSA). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively that make up EndeavourRx LLC, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors that make up ResolutionRx Ltd. Certain therapeutic opportunities have been retained at RespireRx.

The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.

EndeavourRx LLC: Neuromodulators

AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, SCI, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.

AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants. In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of SCI. The DOD has provided a notice of award to our collaborator, the Shirley Ryan AbilityLab, of $1.8 million to fund a Phase 2A/2B clinical study of CX1739 in individuals with SCI.

EndeavourRx LLC will continue RespireRx’s focus on its AMPAkines programs.

GABAkines. Under an Amended and Restated Patent License Agreement entered into as of October 27, 2025 with the University of Wisconsin-Milwaukee Research Foundation, Inc. and on behalf of its EndeavourRx LLC subsidiary, RespireRx has in-licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific, subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx LLC will continue RespireRx’s focus on developing KRM-II-81 for the treatment of epilepsy and pain.

KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant animal and other models (34 models). Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy because of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM- II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment-resistant epileptic patients who underwent surgery (3 studies). We have also licensed and characterized the anti-seizure properties of a host of structural analogs of KRM-II-81 that will facilitate the overall development of this program.

In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies (7 studies and other GABAkines in our portfolio in 3 additional studies). KRM-II-81 is currently being profiled for its analgesic and side-effect profile by the Division of Translational Research, at the NINDS. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid analgesics that are at the heart of the opioid epidemic.

On September 23, 2025, RespireRx received a Notice of Award from the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), award number 1R44NS143576, under the Small Business Innovation Research (SBIR) program which was created by the U.S. Congress to strengthen the role of small innovative companies in federally supported research and development. The amount of the award is $1,499,869 for the budget period September 23, 2025 through August 31, 2026. The project start date is September 23, 2025 and end date is August 31, 2027, a two-year period. The total amount requested in the application was $2,999,738 over the two-year period. The purpose of the project is to complete the required preclinical toxicology and other related efforts to support the filing of an investigational new drug application (IND) to study in clinical trials, our lead GABAkine, KRM-II-81 for the treatment of epilepsy. This content is solely the responsibility of the Company, and any writings, publications, presentation or similar disclosures are solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

ResolutionRx Ltd: Pharmaceutical Cannabinoids.

ResolutionRx Ltd (Australian Company Number a/k/a ACN 664 925 651) was formed in Australia on January 11, 2023 by RespireRx as an unlisted public company. RespireRx has contributed by sublicense and license with ResolutionRx, its obstructive sleep apnea drug development program subject to certain liabilities. ResolutionRx now engages in the research and development (R&D) associated with that program, initially for the development of a new formulation of dronabinol for use in an anticipated pharmacokinetic and pharmacodynamic study of the lead new formulation to be followed by a Phase 3 clinical trial and the filing of regulatory approval for the treatment of OSA. The current total budget for that program over the next several years is approximately US$16.5 million, most, but not all of which is expected to be eligible for the Australian R&D Tax Incentive (R&DTI). The R&DTI in the case of ResolutionRx is anticipated to be approximately 43.5% of qualified R&D expenditures. Dronabinol, an endocannabinoid receptor agonist, has already demonstrated significant improvement in the symptoms of OSA in two Phase 2 clinical trials. OSA is a serious respiratory disorder that impacts an estimated 90 million people in the United States, Australia, the United Kingdom and Germany and that has been linked to increased risk for hypertension, heart failure, depression, and diabetes. There are no approved drug treatments for OSA. 

Because dronabinol is already FDA approved for the treatment of AIDS related anorexia and chemotherapy induced nausea and vomiting, RespireRx and ResolutionRx further believe that its repurposing strategy would only require, in the United States, approval by the FDA of a 505(b)(2) new drug application (NDA), an efficient regulatory pathway that allows the use of publicly available data. Similar rapid approval strategies are also available in the European Union.

The currently available commercial formulation of dronabinol which is available both as a branded and generic product is not ideal for indications requiring drug to be available for six or more hours. The RespireRx Group’s new formulations, of which one has been designated as the lead formulation for the dronabinol program is believed to overcome a number of the limitations and shortcomings of the current commercial formulation, including but not limited to the possibility of doses lower than those currently in the market (lower than 2.5mg, 5mg or 10mg, the currently available doses).

Additional information about RespireRx and the matters discussed herein can be obtained on the RespireRx website at www.RespireRx.com. Additional information about ResolutionRx and the matters discussed herein can be obtained on the ResolutionRx website at https://www.resolutionrx.com.au. Additional information about EndeavourRx LLC and the matters discussed herein can be obtained on the EndeavourRx website at https://endeavourrx.com.

Not a Securities Offering or Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale of securities would be unlawful before registration or qualification under the laws of such jurisdiction.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company intends that such forward-looking statements be subject to the safe harbor created thereby. These might include statements regarding the Company’s future plans, targets, estimates, assumptions, financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about research and development efforts, including, but not limited to, preclinical and clinical research design, execution, timing, costs and results, future product demand, supply, manufacturing, costs, marketing and pricing factors.

In some cases, forward-looking statements may be identified by words including “assumes,” “could,” “ongoing,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” “anticipates,” “believes,” “intends,” “estimates,” “expects,” “plans,” “contemplates,” “targets,” “continues,” “budgets,” “may,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words, and such statements may include, but are not limited to, statements regarding (i) future research plans, expenditures and results, (ii) potential collaborative arrangements, (iii) the potential utility of the Company’s product candidates, (iv) reorganization plans, and (v) the need for, and availability of, additional financing. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release.

These factors include but are not limited to, regulatory policies or changes thereto, available cash, research and development results, issuance of patents, competition from other similar businesses, interest of third parties in collaborations with us, and market and general economic factors, and other risk factors disclosed in “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on April 17, 2023 (the 2022 Form 10-K). We have not filed our Annual Report on Form 10-K for the year ended December 31, 2023 or for the year ended December 31, 2024, nor have we filed our quarterly Current Reports on Form 10-Q as of March 31, 2024, June 30, 2024, September 30, 2024, March 31, 2025, June 30, 2025 or September 30, 2025.

You should read these risk factors and the other cautionary statements made in the Company’s filings as being applicable to all related forward-looking statements wherever they appear in this press release. We cannot assure you that the forward-looking statements in this press release will prove to be accurate and therefore current and prospective investors, as well as current and potential collaborators and other current and potential stakeholders, are encouraged not to place undue reliance on forward-looking statements. You should read this press release completely. Other than as required by law, we undertake no obligation to update or revise these forward-looking statements, even though our situation may change in the future. 

We caution current and prospective investors, as well as current and potential collaborators and other current and potential stakeholders, not to place undue reliance on any forward-looking statement that speaks only as of the date made and to recognize that forward-looking statements are predictions of future results, which may not occur as anticipated. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described in the 2022 Form 10-K, in our quarterly reports on Form 10-Q, in our Current Reports on Form 8-K, and other reports that we file with or furnish to the SEC and in this press release, as well as others that we may consider immaterial or do not anticipate at this time. These forward-looking statements are based on assumptions regarding the Company’s business and technology, which involve judgments with respect to, among other things, future scientific, economic, regulatory and competitive conditions, collaborations with third parties, and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. Our expectations reflected in our forward-looking statements can be affected by inaccurate assumptions that we might make or by known or unknown risks and uncertainties, including those described in the 2022 Form 10-K, in our quarterly reports on Form 10-Q, in our Current Reports on Form 8-K, and other reports that we file with or furnish to the SEC and in this press release. These risks and uncertainties are not exclusive and further information concerning us and our business, including factors that potentially could materially affect our financial results or condition, may emerge from time to time. For more information about the risks and uncertainties the Company faces, see “Item 1A. Risk Factors” in our 2022 Form 10-K. Forward-looking statements speak only as of the date they are made. The Company does not undertake and specifically declines any obligation to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments. We advise current and prospective investors, as well as current and potential collaborators and other current and potential stakeholders, to consult any further disclosures we may make on related subjects in our annual reports on Form 10-K and other reports that we file with or furnish to the SEC including but not limited to our most recent Form 10-Q as of September 30, 2023 filed with the SEC on November 17, 2023. As noted above, we have not yet filed our Annual Report on Form 10-K for the year ended December 31, 2023 or for the year ended December 31, 2024, nor have we filed our quarterly reports on Form 10-Q as of March 31, 2024, June 30, 2024, September 30, 2024, March 31, 2025, June 30, 2025 or September 30, 2025.

Company Contact:

November 20, 2025 9:30 AM EST | Source: Metaguest.AI Incorporated
Toronto, Ontario--(Newsfile Corp. - November 20, 2025) - Metaguest.AI Incorporated (CSE: METG) (OTCQB: MGSTF) ("Metaguest" or the "Company") an AI technology company transforming the hospitality sector through intelligent guest engagement, announces its third quarter, September 30, 2025, unaudited results.

Nine-month revenue ended September 30, 2025, grew 91% year-over-year to $1,930,477 (2024 - $1,008,901), reflecting expansion across North America and a growing installed base of hotel partners.

Three-month revenue ended September 30, 2025, increased 38% to $625,623, compared with $452,978 for the comparative period, driven by broader customer adoption and higher platform engagement.

Gross profit for the nine-month period rose 90% to $1,643,038, up from $864,568 in the prior nine-month period.

Net loss improved by 30% period-over-period, decreasing to $1,305,425 from $1,873,762, primarily due to revenue growth and disciplined cost management.

"Our third quarter results demonstrate strong period-over-period revenue growth and continued customer adoption across North America," said Antonio Comparelli, Chief Executive Officer. "As we enter 2026, our focus remains on accelerating deployment with hotel partners and expanding our AI-driven guest engagement ecosystem."

About Metaguest.AI Incorporated

Metaguest.AI is a next-generation technology company focused on enhancing the guest experience through advanced AI solutions. Its flagship platform provides an end-to-end guest engagement ecosystem, covering everything from pre-arrival to post-departure. Features include on-property e-commerce with digital payments, real-time service requests, mobile check-out, personalized in-room controls, local experience and event bookings, and a multilingual virtual concierge-all accessible without downloading an app or visiting a website. Hotels, resorts, and short-term rental operators use Metaguest to boost efficiency, drive incremental revenue, and elevate customer satisfaction.

For more information about Metaguest and its innovative digital concierge services, please visit http://www.metaguest.ai or please contact:

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275304

CEO's personal open-market investment reflects long-term alignment with shareholders and continued commitment to transparency, excellence and innovation. MESA, ARIZONA / ACCESS Newswire / November 20, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) (the "Company") today announced that its Chief Executive Officer, Marshall Perkins, purchased 50,000,000 shares of MDCE common stock on the open market at an average purchase price of $0.0003 per share on November 19, 2025.

"Welcome to the melt up," says Kevin Hincks, as markets soared ahead of Thursday's opening bell. It's no secret that Nvidia's (NVDA) earnings served as the catalyst, with leadership appearing to quell fears of an A.I.

American Resources Corp (NASDAQ:AREC) said on Thursday its rare earth refining affiliate ReElement Technologies signed a commercial processing agreement with Electronic Recyclers International (ERI) to source and refine end-of-life magnet materials into high-purity rare earth oxides.

ERI, the largest electronics recycler in the US, will use its international collection network and eight US recycling centers to aggregate and pre-process magnet-bearing materials.

ReElement will then refine the feedstock into high-purity rare earth oxides for use in mobility, defense and advanced technology applications, the company said.

American Resources said the partnership bolsters efforts to build a domestic, circular supply chain for rare earths amid rising strategic demand. ERI uses proprietary, AI-driven systems to identify and extract magnet materials at purity levels that enable the recovery of critical minerals.

ReElement has begun trial shipments of rare earth oxides with purity above 99.99% to commercial and defense partners and is taking orders for refined materials. Production is underway at its Noblesville, Indiana facility, with large-scale output expected to shift to its 400,000-square-foot complex in Indiana starting in early 2026.

“Pairing [ERI’s] feedstock capabilities with ReElement's advanced refining platform positions us to accelerate true circularity for critical minerals in the United States and deliver high-purity rare earth elements for our current and expanding customer base,” Mark Jensen, ReElement’s CEO, said.

"ReElement's groundbreaking technology and solutions make it the leading refiner of high-performance critical battery and rare earth elements required in energy, transportation, defense and other technologies,” ERI's CEO John Shegerian said.

“This new relationship will open the door for a whole new wave of US-based capabilities in the rare earth realm that will have both domestic and global implications.”

Analyst’s Disclosure:I/we have a beneficial long position in the shares of IFS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Atlanta, GA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI): Trust Stamp, a global provider of AI-powered software solutions focused on identity and trust, today announced its selection for the 2026 Trust Village Incubator, an initiative powered by EPFL Innovation Park, Trust Valley, SICPA and Canton de Vaud.The selection recognizes Trust Stamp’s pioneering work in privacy-preserving identity technology, particularly its latest innovation, StableKey™, built upon the company’s patented Stable IT2 cryptosystem. The StableKey solution introduces a groundbreaking approach to biometric authentication by enabling secure identity verification without storing any sensitive biometric data or private cryptographic keys.

Gareth N. Genner, CEO of Trust Stamp, commented, “We are honored to join the Trust Valley ecosystem and participate in the Trust Village programme in Switzerland. This collaboration will accelerate our mission to redefine how privacy, trust, and security intersect in the digital economy. Switzerland’s leadership in trust technologies, blockchain, and digital identity makes it an ideal environment for bringing StableKey to market.”

During the six-month incubation programme, Trust Stamp aims to:

Execute its European go-to-market strategy for StableKey™;Build partnerships with financial institutions, blockchain innovators, and identity providers across Switzerland and the EU;Launch pilot projects that demonstrate privacy-preserving authentication for digital assets, self-custody wallets, and trusted credentials; andStrengthen its alignment with European digital trust frameworks, including eIDAS 2.0. The Trust Village connects startups, research institutions, and industry leaders in digital trust and cybersecurity. Participation will give Trust Stamp access to institutional partners and the Swiss trust-tech community, enabling the company to accelerate commercialization, expand its European presence, and demonstrate the impact of Stable Key across digital identity markets. Dr. David Grima, Director of Product Innovation, will represent Trust Stamp in Switzerland throughout the programme, engaging with ecosystem partners on-site.

About Trust Stamp

Trust Stamp is a global provider of AI-powered services for use in multiple sectors including banking and finance, regulatory compliance, government, healthcare, real estate, communications, and humanitarian services. Its technology empowers organizations via advanced solutions that reduce fraud, tokenize and secure data, securely authenticate users while protecting personal privacy, reduce friction in digital transactions, and increase operational efficiency, enabling customers to accelerate secure financial inclusion and reach and serve a broader base of users worldwide.

With team members from twenty-two nationalities in eight countries across North America, Europe, Asia, and Africa, Trust Stamp trades on the Nasdaq Capital Market (Nasdaq: IDAI).

About Trust Village

It takes a village to build great cybersecurity and digital trust companies.This is why Trust Village is located in SICPA’s unlimitrust campus, the global center for the Economy of Trust. This campus brings early-stage companies at the heart of a vibrant ecosystem, mixing large corporations, investors and innovators, as well as advisors and experts in one place. Trust Village is where cybersecurity and digital trust innovations happen through dedicated mentoring, collaborative open space and a unique community of innovators and industry experts. Powered by EPFL Innovation Park, Trust Valley, SICPA and Canton de Vaud, Trust Village’s ambition is to invite founders to be part of a community of trust-related innovators and industry leaders that can help them build meaningful and sustainable businesses.

Safe Harbor Statement: Caution Concerning Forward-Looking Remarks 

All statements in this release that are not based on historical fact are “forward-looking statements” including within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The information in this announcement may contain forward-looking statements and information related to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events-based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Inquiries:

David Grima: [email protected]
Gareth Genner: [email protected] 

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) --  House of Doge, the official corporate arm of the Dogecoin Foundation, along with merger partner Brag House Holdings Inc. (NASDAQ: TBH), today celebrates the launch of the 21Shares 2x Long Dogecoin ETF (Ticker: TXXD) (the “Fund”). Launched by House of Doge partner 21Shares, one of the world’s leading issuers of crypto exchange-traded funds (ETFs), TXXD will offer investors leveraged exposure to one of the most dynamic and community-driven assets in the digital asset market. The new ETF will begin trading on NASDAQ on November 20, 2025.

The 21Shares 2x Long Dogecoin ETF (TXXD) is designed to provide investors with twice (2x) the daily performance of Dogecoin (DOGE), before fees and expenses. The ETF allows investors to gain leveraged exposure to Dogecoin through a regulated, exchange-traded structure that can be purchased directly through their bank or broker.

21Shares 2x Long Dogecoin ETF (TXXD)

TickerISINExchangeCurrencyFeeInception DateIssuerTXXDUS53656G1756NASDAQUSD1.89%November 20, 202521Shares US LLC TXXD builds on 21shares’ exclusive partnership with the House of Doge, the official corporate arm of the Dogecoin Foundation. 21Shares and House of Doge serve as equal partners building new opportunities across the Dogecoin ecosystem, all supported by the Foundation. Earlier this year, 21shares launched the only Dogecoin ETP in Europe, globally endorsed by the Dogecoin Foundation, marking a significant milestone in bringing institutional-grade access to Dogecoin. The collaboration highlights Dogecoin’s evolution from an internet meme to a leading decentralized digital asset, supported by real-world utility, growing merchant adoption, and a uniquely engaged global community.

Dogecoin’s ecosystem continues to mature, with major companies such as Tesla and AMC Theatres accepting it for payments. The community’s guiding principle – “Do Only Good Everyday” – has inspired charitable and financial inclusion initiatives around the world, showcasing the cultural and social impact of decentralized finance.

“Dogecoin represents one of the most vibrant and enduring communities in crypto, and this new ETF gives investors a simplified way to participate in its growth,” said Federico Brokate, Global Head of Business Development at 21shares. “With TXXD, investors can access leveraged exposure to Dogecoin through a regulated and transparent structure – combining transparency, liquidity, and institutional-grade reliability.”

“Our mission has always been to support the Dogecoin community and expand what’s possible for the ecosystem,” said Marco Margiotta, CEO of House of Doge. “This new ETF reflects the strength and momentum of a growing community of investors that continue to shape the future of crypto.”

“This marks a defining moment not just for House of Doge, Brag House Holdings, and our partners at 21Shares, but it also reinforces the Dogecoin vision, a vision that’s always been powered by community, creativity, and infinite possibilities, said Lavell Juan Malloy II, CEO of Brag House. With the launch of TXXD, we’re putting the full force of Dogecoin’s energy onto NASDAQ, unlocking double the opportunity for investors, partners and shareholders. Dogecoin’s journey isn’t just about market innovation, it’s about everyday people rewriting what digital inclusion looks like. We strongly believe in the spirit of 'Do Only Good Everyday,' This is just the beginning, and together, our community will make history, one block at a time."

The 21Shares 2x Long Dogecoin ETF aims to deliver 200% of Dogecoin’s daily performance, before fees and expenses. Due to daily compounding, performance over periods longer than one day may differ significantly from twice the underlying asset’s performance. Leveraged ETFs are intended for short-term use by sophisticated investors who actively monitor their positions and understand the risks of high-volatility exposure.

This launch comes on the heels of 21shares’ acquisition by FalconX, the leading global digital asset prime brokerage, announced earlier this year.

About House of Doge

House of Doge is the official corporate arm of the Dogecoin Foundation, committed to advancing Dogecoin ($DOGE) as a widely accepted and decentralized global currency. By investing in the infrastructure needed to bring Dogecoin into everyday commerce, House of Doge is building secure, scalable, and efficient systems for real-world use. From payments and financial products to real-world asset tokenization and cultural partnerships, House of Doge is leading the next era of crypto utility, where Dogecoin goes beyond the meme and fulfills its mission of Doing Only Good Everyday on a global scale.

About 21shares

21shares is one of the world’s leading cryptocurrency exchange traded product (ETP) providers and offers one of the largest suites of crypto ETPs in the market. The company was founded to make cryptocurrency more accessible to investors, and to bridge the gap between traditional finance and decentralized finance. 21shares listed the world’s first physically-backed crypto ETP in 2018, building a seven-year track record of creating crypto ETPs that are listed on some of the biggest, most liquid securities exchanges globally. Backed by a specialized research team, proprietary technology, and deep capital markets expertise, 21shares delivers innovative, simple and cost-efficient investment solutions.

21shares is a subsidiary of FalconX, one of the world's largest digital asset prime brokers. For more information, please visit www.21shares.com.

About Brag House

Brag House is a leading media technology gaming platform dedicated to transforming casual college gaming into a vibrant, community-driven experience. By seamlessly merging gaming, social interaction, and cutting-edge technology, the Company provides an inclusive and engaging environment for casual gamers while enabling brands to authentically connect with the influential Gen Z demographic. The platform offers live-streaming capabilities, gamification features, and custom tournament services, fostering meaningful engagement between users and brands. For more information, please visit www.braghouse.com.

Media Contacts

21shares
Audrey Belloff: [email protected]
Alethea Jadick: [email protected]
Brag House Holdings
Fatema Bhabrawala
Director of Media Relations [email protected]

House of Doge
Angela Gorman
Communications Director
Email: [email protected]
Tel: (917) 348-0083

Investor Relations Contact
Brag House Holdings
Adele Carey
VP, Investor Relations
[email protected]

An investor should consider the investment objectives, risks, charges, and expenses of the Fund carefully before investing. The prospectus and, if available, the summary prospectus contain this and other information about the Fund. You may obtain a prospectus and, if available, a summary prospectus by downloading the prospectus from www.21Shares.com or calling (646) 370-6016. Please read the prospectus or summary prospectus carefully before Investing. The Fund is a recently organized investment company with a limited operating history. As a result, prospective investors have a limited track record or history on which to base their investment decision.

Important Disclosures and Risks

Crypto assets, such as DOGE, operate without central authority or banks and are not backed by any government. Crypto assets are often referred to as a “virtual asset” or “digital asset,” and operate as a decentralized, peer-to-peer financial trading platform and value storage that is used like money. A crypto asset is also not a legal tender. Investments linked to DOGE can be highly volatile compared to investments in traditional securities and the Funds may experience sudden and large losses. The markets for DOGE and DOGE-related investments may become illiquid. These markets may fluctuate widely based on a variety of factors. An investor should be prepared to lose the full principal value of their investment suddenly and without warning. A number of factors affect the price and market for DOGE such as new technology and supply and demand for DOGE.

DOGE and DOGE-related investments are relatively new investments. The performance of DOGE-related investments, and therefore the performance of the Fund, may differ significantly from the performance of DOGE.

The use of leverage increases the risk of loss and volatility, and the Fund may not be suitable for all investors. It is intended for sophisticated investors who understand the effects of daily compounding and are able to actively monitor and manage their investments. Investors could lose the entire value of their investment within a single trading day. Leverage may amplify both gains and losses.

The Fund’s goal is not to achieve its stated objective over periods longer than a single day. Compounded daily rebalancing can lead to returns that differ from twice the price performance of DOGE for the same period. The Fund will lose money if the price performance of DOGE is flat over time, and the Fund can lose money regardless of the performance of DOGE due to daily rebalancing, the volatility of the price of DOGE, compounding of each day’s return, and other factors. There is no guarantee that the Fund will meet its stated objective.

Futures investing is highly speculative and involves a high degree of risk. An investor may lose all or substantially all of an investment in the Fund. Investing in commodity interests subjects the Fund to the risks of its related industry.

The Fund is classified as a “non-diversified” investment company under the 1940 Act and may invest a larger percentage of its assets in a single position or issuer than a diversified fund.

The Fund currently intends to effect creations and redemptions principally for cash, rather than principally in-kind because of the nature of the Fund's investments. As such, investments in the Fund may be less tax efficient than investments in ETFs that create and redeem in-kind. The Fund is deemed a commodity pool and is therefore subject to regulation under the Commodity Exchange Act and the rules of the Commodity Futures Trading Commission (CFTC).

An investment in the Fund involves risk, including possible loss of principal. ETFs trade like stocks, are subject to investment risk, fluctuate in market value and may trade at prices above or below the ETF's net asset value (NAV), and are not individually redeemable directly with the ETF. Brokerage commissions and ETF expenses will reduce returns. ETFs are subject to specific risks, depending on the nature of the underlying strategy of the Fund. These risks could include Clearing Broker Risk, Collateral Securities Risk, Cybersecurity Risk, Early Close/Trading Halt Risk, Intra-Day Investment Risk, Market Risk, Reverse Repurchase Agreements Risk, Valuation Risk, Whipsaw Markets Risk, and XRP-Related Investments Tax Risk. For a complete description of the Fund’s principal investment risks, please refer to the prospectus.

Shares of the Fund are not FDIC insured, may lose value, and have no bank guarantee.
Shares are not individually redeemable directly with the Fund. Brokerage commissions and Fund expenses will reduce returns.

PINE Distributors LLC is the distributor for the 21Shares 2X Long DOGE ETF. Teucrium Investment Advisors, LLC serves as the investment adviser and 21Shares US LLC serves as the Subadviser to the 21Shares 2X Long DOGE ETF. PINE Distributors LLC is not affiliated with Teucrium Investment Advisors, LLC or 21Shares US, LLC.

Learn more about PINE Distributors LLC at FINRA’s BrokerCheck TUCRM-XXXXX-XX/25

Construction Partners (ROAD - Free Report) came out with quarterly earnings of $1.07 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.58 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -3.60%. A quarter ago, it was expected that this road and highway construction company would post earnings of $0.87 per share when it actually produced earnings of $0.81, delivering a surprise of -6.9%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Construction Partners, which belongs to the Zacks Building Products - Miscellaneous industry, posted revenues of $899.85 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.79%. This compares to year-ago revenues of $538.16 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Construction Partners shares have added about 17.8% since the beginning of the year versus the S&P 500's gain of 12.9%.

What's Next for Construction Partners?While Construction Partners has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Construction Partners was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.47 on $715 million in revenues for the coming quarter and $2.94 on $3.3 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Building Products - Miscellaneous is currently in the bottom 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Argan (AGX - Free Report) , is yet to report results for the quarter ended October 2025.

This builder of energy plants is expected to post quarterly earnings of $1.65 per share in its upcoming report, which represents a year-over-year change of -17.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Argan's revenues are expected to be $238.93 million, down 7% from the year-ago quarter.

Summary

While the latest reactors built in the U.S. saw severe delays and cost overruns, the United Arab Emirates saw strong success with its first nuclear plant. 
The strong execution of the Barakah plant in the UAE was attributed to rigorous planning, global collaboration, and thorough budgeting.
Nuclear power plants are costly and time-intensive to build, but they also generate zero-emission, reliable baseload power for 80 or more years.

One of the pushbacks to nuclear power is its high, upfront capital costs, which can be potentially exacerbated by cost overruns and delays. This was certainly the case for the last large reactors built in the U.S. in Georgia (Vogtle 3 and 4) and the reactors currently under construction in the UK have also seen challenges. 

While the nuclear projects likely to end up in the newsfeeds of U.S. investors have faced setbacks, other countries have seen better execution on large reactor projects. Admittedly, countries like China benefit from standardization and repetition with multiple projects under construction. However, the United Arab Emirates  (UAE) provides an example of a new entrant to nuclear power that saw very strong execution on building reactors in recent years.

The UAE Example
Historically reliant on fossil fuels, the UAE turned to nuclear energy to secure emission-free power to fuel economic growth. Its four-reactor Barakah plant proves that nuclear power projects can be delivered on schedule and on budget. The first unit took eight years from the initial concrete pour to the start of operations, and efficiencies were realized with the subsequent units. For context, Vogtle 3 in the U.S. took 14 years to complete and was roughly seven years behind schedule.

Rigorous planning, global collaboration, and thorough budgeting are some of the key elements of the UAE’s approach that contributed to its overall success. Potential project partners were evaluated for a year by a team of 75 nuclear experts from around the world. 

Ultimately, Korea Electric Power Corporation (KEPCO) was chosen to design, build, and support the operations of the Barakah Plant. Nuclear reactors that came online in 2016 and 2019 in South Korea using the same technology (APR 1400) served as reference plants for Barakah. KEPCO is a constituent of the Range Nuclear Renaissance Index (NUKZX). 

Why do some projects struggle?
Nuclear projects can be challenging, as they’re often first-of-a-kind facilities, deploying a design that has not been used before. This can understandably create difficulties. In practically, the third or fourth version is easier than the first, and later iterations benefit from prior learnings. Regulations can also contribute to delays and cost overruns, with nuclear projects subject to significant oversight.

Nuclear development becomes better and more efficient with repetition. Certainly, there are efficiency gains from the first to the second or fourth unit on the same site. More broadly, multiple projects under construction in a country would drive more robust supply chains and a stronger workforce. As the U.S. seeks to triple nuclear power capacity by 2050, these are key areas that need support and have been an emphasis in executive orders from the Trump administration (read more). 

Nuclear isn’t simple, but has clear advantages. 
Admittedly, nuclear power plants are costly and time-intensive to build, but they also generate zero-emission, reliable baseload power for decades. As of April 2025, the U.S. Nuclear Regulatory Commission had approved 12 reactors to operate for 80 years, and was reviewing applications from an additional five reactors to extend their licenses to 80 years. Upfront costs are more manageable when viewed through the lens of 80 or more years of operation. For context, the life span for less-reliable solar panels or wind turbines may be 20-30 years. 

Nuclear is also not unique in taking years to develop. Consider oil and gas, where production depletes over time compared to nuclear’s steady output. According to the International Energy Agency, it typically takes 20 years between when exploration licenses are granted and hydrocarbons are actually produced.  

Bottom Line:
Nuclear power projects are expensive and take time. However, their longevity of operation, reliability, and emission-free power generation represent distinct advantages. The UAE provides a prime example of solid execution on large reactors, proving nuclear projects do not have to be plagued with delays and cost overruns.

NUKZX is the underlying index for the Range Nuclear Renaissance Index ETF (NUKZ).

Looking for nuclear insights in your inbox? Subscribe here to keep a pulse on nuclear investing through our weekly research.  

Related Research:
U.S. Military to Use Nuclear Microreactors, Jump-Starting Supply Chain

Nuclear Support: Energy Policy Washington Agrees On

For more news, information, and analysis, visit the Nuclear Energy Content Hub.

vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for NUKZ, for which it receives an index licensing fee. However, NUKZ is not issued, sponsored, endorsed, or sold by VettaFi. VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of NUKZ.

Earn free CE credits and discover new strategies

November 20, 2025 08:30 ET

 | Source:

MarketWise LLC

BALTIMORE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- On October 29, 2025, MarketWise, Inc. (“MarketWise” or the “Company”) (NASDAQ: MKTW), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, received an unsolicited non-binding proposal from Monument & Cathedral Holdings, LLC (collectively with its affiliates, "M&C"), to acquire all of the outstanding equity interests of the Company and Marketwise, LLC that are not owned by M&C, for cash consideration of $17.25 per share (the "Proposal"), contingent upon the termination of the Company’s tax receivable agreement. In the Q3’25 earnings report released on November 6, 2025, the Company disclosed that a Special Committee of the Board of Directors was reviewing the Proposal in consultation with its advisors.

The mandate of the Special Committee is to evaluate the Proposal and any alternatives thereto that may be available to the Company. The Special Committee has retained Centerview Partners LLC as its financial advisor and Kirkland & Ellis LLP as its legal advisor.

There can be no assurance that any transaction will result from the Special Committee's evaluation, or, if so, the timing, terms and conditions of any such transaction. MarketWise does not intend to comment on or disclose further developments with respect to this matter unless and until further disclosure is appropriate or required.

About MarketWise

Founded with a mission to level the playing field for self-directed investors, today MarketWise is a leading multi-brand subscription services platform providing premium financial research, software, education, and tools for investors.

With more than 25 years of operating history, MarketWise serves a community of millions of free and paid subscribers. MarketWise’s products are a trusted source for high-value financial research, education, actionable investment ideas, and investment software. MarketWise is a 100% digital, direct-to-customer company offering its research across a variety of platforms including mobile, desktops, and tablets. MarketWise has a proven, agile, and scalable platform and our vision is to become the leading financial solutions platform for self-directed investors.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the financial position, business strategy, the plans and objectives of management for future operations, and the potential for future transactions. These forward-looking statements generally are identified by the words “estimate,” “believe,” “project,” “expect,” “anticipate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, but not limited to: our ability to attract new subscribers and to persuade existing subscribers to renew their subscription agreements with us and to purchase additional products and services from us; our ability to adequately market our products and services, and to develop additional products and product offerings; our ability to manage our growth effectively, including through acquisitions; failure to maintain and protect our reputation for trustworthiness and independence; our ability to attract, develop, and retain capable management, editors, and other key personnel; our ability to grow market share in our existing markets or any new markets we may enter; adverse or weakened conditions in the financial sector, global financial markets, and global economy; current macroeconomic events, including heightened inflation, rise in interest rates and the potential for an economic recession; failure to comply with laws and regulations or other regulatory action or investigations, including the Investment Advisers Act of 1940, as amended; our ability to respond to and adapt to changes in technology and consumer behavior; failure to successfully identify and integrate acquisitions, or dispose of assets and businesses; our public securities’ potential liquidity and trading; the impact of the regulatory environment and complexities with compliance related to such environment; our future capital needs; our ability to maintain an effective system of internal control over financial reporting, and to address and remediate existing material weaknesses in our internal control over financial reporting; and other factors beyond our control.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our filings with the U.S. Securities and Exchange Commission (the “SEC”). These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. We do not give any assurance that we will achieve our expectations.

MarketWise Investor Relations Contact
Email: [email protected]

MarketWise Media Contact
Email: [email protected]

November 20, 2025 08:30 ET

 | Source:

Intelligent Bio Solutions, Inc.

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference, taking place over December 2-3, 2025, in Boca Raton, Florida.

Conference Details
Date:  December 2–3, 2025
Location:  Florida Atlantic University, Boca Raton, FL
Presentation Date and Time: Wednesday, December 3, 2025, 11:00 a.m. Eastern Time
Presentation Location:  Presentation Room 2

A webcast recording of INBS’s presentation will be available the following day on INBS’s investor relations website, as well as Noble’s website and on Channelchek, for 90 days after the event.

Interested investors can register to attend here using the discount code INBSNOBLECON.

For more information about the conference, or to schedule a one-on-one meeting with the INBS management team, please contact your Noble Capital Markets representative or email KCSA Strategic Communications at [email protected].

About Intelligent Bio Solutions Inc.   

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.   

For more information, visit https://ibs.inc/ 

Company Contact  

Intelligent Bio Solutions Inc.   
[email protected]    
LinkedIn | Twitter   

Investor & Media Contact  

Valter Pinto, Managing Director   
KCSA Strategic Communications   
PH: (212) 896-1254   
[email protected]  

November 20, 2025 08:30 ET

 | Source:

America's Car-Mart, Inc.

ROGERS, Ark., Nov. 20, 2025 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) today announced it will release fiscal 2026 second quarter financial results on Thursday, December 4, 2025, before the market opens. A webcast and conference call will be held that same day at 9:00 a.m. ET to review the Company’s results.

Participants may access the conference call via webcast using this link: Webcast Link Here. To participate via telephone, please register in advance using this Registration Link. Upon registration, all telephone participants will receive a one-time confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call. All participants are encouraged to dial-in 10 minutes prior to the start time.

A replay of the conference call and webcast will be available on-demand at the Car-Mart Investor Relations website for 12 months from December 4, 2025.

About America's Car-Mart

America’s Car-Mart operates automotive dealerships in 12 states and is one of the largest publicly held automotive retailers in the United States focused exclusively on the “Integrated Auto Sales and Finance” segment of the used car market. The Company emphasizes superior customer service and the building of strong personal relationships with its customers. The Company operates its dealerships primarily in smaller cities throughout the South-Central United States, selling quality used vehicles and providing financing for substantially all of its customers. For more information about America’s Car-Mart, including investor presentations, please visit our website at www.car-mart.com.

Contact:        
SM Berger & Company
Andrew Berger, Managing Director
[email protected]
(216) 464-6400

November 20, 2025 08:30 ET

 | Source:

ICU Medical, Inc.

SAN CLEMENTE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference being held in New York, December 2-4, 2025. ICU Medical’s fireside chat will be on Thursday, December 4, 2025 at 10:00 a.m. PT (1:00 p.m. ET). Company management will also be participating in one-on-one meetings on Thursday, December 4, 2025.

The fireside chat will be webcast live and can be accessed by going to the Company’s website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab. The webcast will also be available by replay.

About ICU Medical

ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com.

CONTACT:
ICU Medical
Brian Bonnell, Chief Financial Officer
(949) 366-2183

ICR, Inc.
John Mills, Managing Partner
(646) 277-1254

Source: ICU Medical, Inc.

Snail, Inc. to unveil significant updates to its Stablecoin initiative and upcoming ARK: Lost Colony DLC

November 20, 2025 08:30 ET

 | Source:

Snail, Inc.

CULVER CITY, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced it will host its Investor Day on December 16, 2025 at 12:00 p.m. Eastern time, at the NASDAQ MarketSite in New York City. The event will bring together shareholders, analysts, investors, and qualified members of the press for a strategic overview of the Company’s direction heading into 2026.

The event will give investors and analysts a deeper insight into Snail’s ongoing initiatives, upcoming product expansions, and long-term vision. In addition to commentary from Company leadership, attendees will receive updates on key initiatives including:

Stablecoin Project: A closer look at the Company’s previously announced digital asset infrastructure and its potential to strengthen Snail Inc.’s long-term strategy.Upcoming ARK: Lost Colony DLC: Insights into the upcoming expansion designed to extend the product life cycle, deepen engagement, and support continued revenue opportunities. Snail, Inc. CEO Hai Shi commented: “Our upcoming Investor Day gives us the opportunity to outline how our upcoming initiatives are designed to support a more resilient and scalable business model. With many exciting updates and unveilings coming on December 16 across a multitude of projects we are currently working on, we look forward to connecting with our investor community and sharing how our current strategic advancements position us for sustainable growth in the years ahead.”

Attendance is open to analysts, shareholders, investors and qualified members of the press. For more information, please contact

[email protected].

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit:

https://snail.com/ Forward-Looking Statements 

This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and in certain of our public filings with the SEC and include, but are not limited to, statements regarding Snail’s ongoing initiatives, upcoming product expansions, and long-term vision and the potential strategic advancements that may position the Company for sustainable growth in the years ahead. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed by the Company with the SEC on March 26, 2025 and other documents filed by the Company from time to time with the SEC, including the Company's Forms 10-Q filed with the SEC. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860

[email protected]

Intel (INTC)’s stock surged 75% this year, not just due to revenue growth but also a significant increase in its valuation multiple.

Signage with logo at the Silicon Valley headquarters of computer hardware manufacturer Intel, Santa Clara, California, August 17, 2017. (Photo via Smith Collection/Gado/Getty Images).

Getty Images

This jump is supported by a series of unexpected events: strategic investments in AI, new funding, cost reductions, and a strong rebound in Q3. Let’s explore the narrative that is propelling this increase.

Here’s a detailed analysis of the stock's movements and the key metrics contributing to them.

INTC Summary

Trefis

What’s going on here? The stock increased by 75%, in six months, driven by a modest 0.7% rise in revenue alongside an impressive 81% increase in the valuation multiple. Let’s delve into the details that led to these changes.

Reasons Behind Intel Stock Movement

AI Strategy & Products: Intel is prioritizing AI, introducing new Core Ultra processors (Panther Lake on 18A) for AI-focused PCs set to launch in late 2025.Government & Investor Funding: Large investments came from Nvidia ($5B), SoftBank ($2B), and the U.S. Government ($8.9B under the CHIPS Act).Q3 2025 Earnings Beat: Intel surpassed Q3 2025 revenue and EPS forecasts, achieving an adjusted profit of $0.23 per share.Cost Cuts & Restructure: Ongoing efforts to reduce costs led by CEO Lip-Bu Tan have enhanced financial oversight.What Next

MORE FOR YOU

Intel must demonstrate strong 18A-class yields at scale and secure early foundry customers to reinforce confidence in its manufacturing turnaround.Intel’s collaboration with Nvidia—manufacturing custom x86 processors for Nvidia’s AI systems—must stay on schedule to validate its relevance in next-gen data-center compute.Delivering the next-generation Nova Lake desktop architecture on time is essential for restoring performance leadership and stabilizing Intel’s core PC business.Our Current Assessment of INTC Stock

Opinion: At present, we regard INTC stock as unappealing. Why is that? You can check out the full explanation. View Buy or Sell INTC Stock to understand what informs our current viewpoint.

Risk: A good method to measure Intel’s risk is by observing its declines during significant market downturns. It fell approximately 74% during the Dot-Com crash, 55% in the Global Financial Crisis, and 62% amid the inflation crisis. Even during less severe events, such as the 2018 correction and the COVID-19 pandemic, it experienced declines of 25% and 35%, respectively. While solid fundamentals are important, Intel is still vulnerable to significant drops when the market changes.

Although INTC stock has experienced significant gains lately, investing in a single stock without a comprehensive and detailed analysis can be risky. The Trefis High Quality (HQ) Portfolio, consisting of 30 stocks, has a history of consistently outperforming its benchmark, which encompasses all three — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a collective, the HQ Portfolio stocks offered superior returns with lower risk compared to the benchmark index; they provided a more stable ride, as shown in HQ Portfolio performance metrics.

Stock futures are surging this morning after Nvidia's highly anticipated quarterly results and outlook handily topped Wall Street expectations; Walmart released results that beat analysts' estimates on the top and bottom lines; the jobs report for September is finally set to arrive after its release was delayed by the government shutdown; and shares of Palo Alto Networks are losing ground after the cybersecurity firm released earnings and announced an acquisition. Here's what investors need to know today.

Stocks Surge As Investors Cheer Blockbuster Report From Nvidia
Stocks futures are pointing to a sharply higher open for major indexes this morning after AI darling Nvidia's (NVDA) earnings report and outlook, released after yesterday's closing bell, blew past expectations. The strong numbers from the chip giant are giving a boost to technology stocks broadly, amid revived confidence in the AI trade that has sent stocks to a series of record highs this year. Futures tied to the Dow Jones Industrial Average and the S&P 500, which each snapped four-day losing streaks yesterday, were recently up 0.7% and 1.3%, respectively. Futures linked to the tech-heavy Nasdaq were up 1.8%. Bitcoin was at $91,600 recently, after falling to its lowest level since April below $90,000 yesterday. Gold futures were down slightly at 4,075 an ounce, while the yield on the 10-year Treasury note, which affects borrowing costs on a range of consumer loans, was little changed at 4.14%.

Nvidia Stock Jumps After Earnings, Lifting Tech Sector
Nvidia shares are surging Thursday after the chipmaker's fiscal 2026 third quarter results handily topped estimates, temporarily cooling fears of an AI bubble that have shaken markets and slowed tech stocks in recent weeks. Third-quarter revenue of $57 billion and adjusted earnings per share of $1.30 were each higher than analysts had estimated, as the company at the center of the AI boom managed to exceed sky-high expectations. Nvidia projected revenue in the current quarter of $65 billion, with CEO Jensen Huang saying that sales of its Blackwell AI platform are "off the charts." Nvidia shares were up more than 5% in recent premarket trading, while other chip stocks, including Advanced Micro Devices (AMD), Broadcom (AVGO), Arm Holdings (ARM) and Micron Technology (MU) also rose sharply. All of the Magnificent 7 stocks were gaining ground this morning.

Walmart Tops Q3 Estimates, Announces Shift of Listing From NYSE to Nasdaq
Walmart (WMT), which recently announced the departure of long-time CEO Doug McMillon, this morning reported results that topped analysts' expectations. The retail giant reported adjusted earnings per share of $0.62 on revenue of $179.5, each better than analysts had forecast. Comparable sales rose 4% from the same time a year ago, also just above the analyst consensus. Also on Thursday, Walmart announced plans to shift its listing from the New York Stock Exchange to the Nasdaq, retaining its "WMT" ticker and expecting to complete the move by Dec. 9. Walmart shares—which have gained about 11% this year, slightly lagging the performance of the S&P 500—were up less than 1% in recent premarket trading.

Delayed September Jobs Report Due Out This Morning
The long-delayed jobs report for September is due out this morning at 8:30 a.m. ET. The report was initially scheduled for release on October 3, but the onset of the 43-day government shutdown delayed that and other economic data from being released, with the Bureau of Labor Statistics saying some October data may never be released. U.S. employers are projected to have added around 51,000 jobs in September, above the 22,000 added in August but still well below the average mark of 147,000 for the last year through April 2025. The unemployment rate is expected to remain around 4.3%. The jobs numbers will factor into the Federal Reserve's upcoming decision on interest rates at its next meeting on Dec. 9 and 10. Fed officials seem to be split on whether to cut or hold rates steady.

Palo Alto Networks Stock Slips After Earnings, Acquisition
Shares of Palo Alto Networks (PANW) are down this morning after the cybersecurity firm' released its quarterly results and announced an acquisition. The company reported $2.47 billion in revenue for its first quarter of fiscal 2026, in line with analysts' estimates, and adjusted earnings per share of $0.93, slightly better than expected. Its forecasts for the second quarter and full fiscal year were also roughly in line with the analyst consensus, but investors may have been hoping for more impressive projections. The software maker also announced plans to acquire AI cybersecurity company Chronosphere for $3.35 billion. Palo Alto stock was down 3% before the bell.

Do you have a news tip for Investopedia reporters? Please email us at

[email protected]

Key Takeaways

Open Q&A with new AI leadership
PTOP will host a live Q&A on November 26, 2025, at 6:00 pm ET featuring Derek McCarthy, newly appointed President of Intelligence Labs, alongside CEO Joshua Sodaitis.
20+ years of capital markets experience
Derek brings more than two decades of investor relations, capital markets, and corporate communications expertise across NASDAQ, NYSE, and OTC issuers.
2026 AI commercialization focus
The call will cover Intelligence Labs’ AI product roadmap, early traction, and how PTOP will deploy AI to enhance marketing, compliance, and investor communications.

CAMBRIDGE, Mass., Nov. 20, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Peer To Peer Network, Inc. (OTC: PTOP) it’s pleased to invite investors and potential customers to join an open introduction call with the new AI division president. 

Peer-To-Peer Network, Inc. (OTC: PTOP) today announced it will host an open Question-and-Answer call with Derek McCarthy, recently appointed President of the Company’s rapidly expanding AI division, Intelligence Labs. Chairman and CEO Joshua Sodaitis will also be on the call. Call will be set for Wednesday, 11-26-2025, at 6:00pm Eastern Time.

The virtual event will provide shareholders, investors, and CEOs the opportunity to hear directly from Derek about his strategic vision, background, and the AI product commercialization strategy for PTOP in 2026.

With more than 20 years of investor relations, capital markets, and corporate communications experience, Derek has worked across NASDAQ, NYSE, and OTC companies, helping guide executive teams through the capital markets, public listings, product launches, and investor campaigns. Derek joins PTOP with an established reputation for building scalable marketing systems, AI-powered investor-engagement tools for growth-stage public companies.

During the call, Derek will discuss:

His two decades of investor relations and capital markets experience
The development roadmap and capabilities of PTOP’s growing AI product suite
Early traction from the Intelligence Labs division
How the Company plans to use AI to enhance marketing, compliance, and investor-facing communications
Key near-term and long-term objectives for Intelligence Labs and PTOP

“I’m genuinely excited to meet the PTOP shareholders and answer their questions directly,” said Derek McCarthy, President of Intelligence Labs. 

“We have a tremendous opportunity in front of us. Our AI development roadmap is strong; our product capabilities are being established so I look forward to sharing how Intelligence Labs will drive the next phase of growth for PTOP.”

“This is a great opportunity for people to understand our new division and get to meet a brilliant addition to the PTOP team,” concluded Chairman & CEO Joshua Sodaitis.

Call-In Details:

Date: Wednesday 11-26-2025

Time: 6:00 pm Eastern Time

Join the meeting using one of these easy options:

1) One Tap Mobile Dialing: +17124510637,212732

2) Tap here to have us call you: https://www.freeconferencecall.com/backup?dial_number=7124510637&access_code=212732

3) Join online for Video and Screen Sharing: https://join.freeconferencecall.com/joshsmobicardinc

Additional Options to connect:

Dial-in number (US): (712) 451-0637

Access code: 212732

Find your local number: https://fccdl.in/i/joshsmobicardinc

Having trouble connecting?

Text ‘Call Me’ to (712) 451-0637 to receive a call back; then dial 212732 to join the meeting. Standard Messaging rates may apply.

About Peer-To-Peer Network (PTOP)

Peer-To-Peer Network is a publicly traded technology company developing advanced digital tools for business communications, investor engagement, and online identity. Through its AI division, Intelligence Labs, PTOP is focused on building a suite of artificial intelligence products designed to enhance compliance, automate corporate communications, and strengthen the connection between companies and their customers or investors. The Company holds multiple technology assets, including its digital business card platform, MobiCard™, backed by several issued utility patents. PTOP’s mission is to deliver scalable, efficient, and modernized solutions that empower organizations to operate at the speed of digital engagement.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future product development, commercialization plans, business strategy, and growth opportunities. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. Peer-To-Peer Network undertakes no obligation to update any forward-looking statements except as required by law.

Media & Investor Contact
Email: [email protected]
Investors Relations: 617-481-1971
Peer-To-Peer Network, Inc. (OTC: PTOP)

Source: Peer To Peer Network, Inc.

ARK Invest purchases more than 460,000 shares of Bullish stock and 215,000 shares of Circle Internet Group stock.